MedTrace Logo

Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)

NCT06768177 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-02

No results posted yet for this study

Summary

Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.

Conditions

  • Erectile Dysfunction Due to General Medical Condition
  • Erectile Dysfunction Following Radical Prostatectomy
  • Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
  • Erectile Dysfunctions

Interventions

DRUG

PRP injection

3 ML OF PRP

DRUG

Alprostadil 20 micrograms

1 ML

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-11-01
Completion
2025-11-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06768177 on ClinicalTrials.gov